Royalty Pharma (RPRX) Stock Analysis: AI Score & Alternative Data
RPRX alt-data: revenue climbing, web traffic lagging
Is Royalty Pharma a buy right now? The alternative data says hold. This RPRX stock analysis is built on the 25+ alternative data signals AltIndex tracks on Royalty Pharma every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 54/100: a Hold. The stock trades at $59.45 with a $34B market cap.
The bullish side of the 90-day ledger: revenue up 15.5% YoY to $670M. The drag: web traffic down 23.3% to 10K monthly visits. That tension is what keeps the score mid-range.
RPRX’s broader alt-data profile also covers job postings (1 open roles), and headcount (112 employees, according to LinkedIn). Every signal links to its own page with full history, the RPRX technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on RPRX is just below.
Royalty Pharma AI Stock Analysis
Royalty Pharma (NASDAQ: RPRX) is a prominent player in the pharmaceutical industry, specializing in purchasing royalties generated from the sales of life-saving therapies and treatments. The company’s unique business model allows it to capture significant cash flows while distributing critical financial resources to research and development entities.
Analysis generated August 2, 2026.
Recent Royalty Pharma Stock Alerts
|
Royalty Pharma | June 27 Insider Alert: Urist Marshall is selling shares |
|
Royalty Pharma | May 29 Insider Alert: Coyne Terrance P. is selling shares |
|
Royalty Pharma | May 22 Insider Alert: Urist Marshall is selling shares |
|
Royalty Pharma | May 17 Insider Alert: Norden Gregory is selling shares |
Royalty Pharma Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 10K | 23.3% | |
| Job Posts | 1 | 0% | |
| LinkedIn Employees | 112 | 3.7% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 4 | 33.3% | |
| Stocktwits Mentions | 0 | 100.0% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 7K | 0% | |
| 4chan Mentions | 0 | N/A |
About Royalty Pharma (RPRX)
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States.
| Price | $59.45 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $34B |
| Year Range | $34 – $60 |
| Dividend Yield | 0% |
| PE Ratio | 31.5 |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Royalty Pharma News
View more → |
Zealand Pharma (CPSE:ZEAL) On Its Royalty Pharma Deal And The Fair Value DebateAugust 12 - Biztoc.com |
Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic InitiativesAugust 3 - GlobeNewswire |
|
Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from NeurimmuneJuly 22 - GlobeNewswire |
|
 |
Neurimmune sells a portion of its royalty interest in cliramitug to Royalty PharmaJuly 22 - PRNewswire |
Royalty Pharma declares third quarter 2026 dividendJuly 17 - GlobeNewswire |
Royalty Pharma Earnings & Financial Performance
View all earnings →Royalty Pharma Insider Trading Activity
View all →| Urist Marshall filed to sell 0 shares at $0.0. Jul 1 '26 |
| Hite Christopher filed to sell 40,000 shares at $0.0. Jun 30 '26 |
| Hite Christopher filed to sell 459,399 shares at $0.0. Jun 30 '26 |
| Hite Christopher filed to sell 40,600 shares at $0.0. Jun 30 '26 |
| Hite Christopher filed to sell 461,953 shares at $0.0. Jun 30 '26 |
Royalty Pharma Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Royalty Pharma
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
BiogenBIIB |
$209.15 0.3% | $31B | 34 |
 |
Alnylam PharmaceuticalsALNY |
$224.60 1.8% | $31B | 67 |
 |
IlluminaILMN |
$193.14 1.2% | $29B | 50 |
 |
IQVIAIQV |
$241.24 1.9% | $39B | 69 |
 |
West Pharmaceutical ServicesWST |
$346.61 0.8% | $25B | 59 |
Explore Royalty Pharma Data
Frequently Asked Questions: Royalty Pharma (RPRX)
Royalty Pharma has an AltIndex AI Score of 54/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
54/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Royalty Pharma (RPRX) stock is $59.45 with a market cap of $34B.
As of today, Royalty Pharma’s PE (Price to Earnings) ratio is 31.5.
View the latest Royalty Pharma insider transactions to see recent buying and selling activity by company executives and directors.
Check the Royalty Pharma congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The RPRX stock price chart above shows Royalty Pharma’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Royalty Pharma technical analysis for RSI, moving averages, and more.
See the stocks similar to Royalty Pharma section on this page for companies in the same industry ranked by market cap and AI Score.
